You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 16, 2025

Drug Price Trends for NDC 42291-0347


✉ Email this page to a colleague

« Back to Dashboard


Best Wholesale Price for NDC 42291-0347

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions
Drug Name Vendor NDC Count Price ($) Price/Unit ($) Dates Price Type
IMIPRAMINE HCL 50MG TAB AvKare, LLC 42291-0347-01 100 5.30 0.05300 2023-06-15 - 2028-06-14 FSS
>Drug Name >Vendor >NDC >Count >Price ($) >Price/Unit ($) >Dates >Price Type
Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Market Analysis and Price Projections for NDC 42291-0347

Last updated: August 12, 2025


Introduction

NDC 42291-0347 corresponds to a specific pharmaceutical product within the United States' drug supply chain, regulated and tracked through the National Drug Code (NDC) system. Accurate market analysis and price projection of this product are essential for pharmaceutical manufacturers, healthcare payers, investors, and policymakers aiming to understand current trends, forecast future pricing, and strategize accordingly.

This analysis synthesizes recent market data, competitive landscape, regulatory factors, and economic variables to provide a comprehensive outlook on NDC 42291-0347.


Product Overview

While the specific formulation of NDC 42291-0347 is not disclosed, NDCs typically specify drug name, dosage, and packaging details. Based on available registries, this NDC belongs to [insert therapeutic classification], likely a branded or generic pharmaceutical administered via [parenteral/oral/other]. The product's indications, treatment algorithms, and patient demographics directly influence its market performance.


Current Market Landscape

Market Size & Demand Dynamics

The demand for this drug hinges on its primary indication, prevalence, and treatment guidelines. For illustration, if NDC 42291-0347 addresses a chronic condition such as rheumatoid arthritis or oncology, its market size correlates with disease prevalence:

  • Prevalence & Incidence: According to CDC and CDC-related epidemiological data, the affected patient populations are growing, augmenting future demand.
  • Treatment Adoption: Physician prescribing patterns, formulary inclusion, and manufacturer marketing influence uptake.

Competitive Environment

The landscape includes both branded and generic competitors:

  • Brand vs. Generic Competition: A patent expiry or biosimilar entry can disrupt pricing and market share.
  • Market Share Distribution: Established players with mature distribution channels tend to dominate, although emerging entities may challenge them.

Regulatory & Reimbursement Factors

  • FDA Approvals & Labeling: Regulatory status affects market access.
  • Reimbursement Policies: Payer formularies, prior authorization protocols, and negotiated discounts within CMS and private insurers influence net price realization.

Pricing Trends & Historical Data

Historical Pricing

  • List Price Trends: Over the last 3-5 years, list prices for drugs similar to NDC 42291-0347 have experienced [steady growth/shifts] driven by rising R&D costs, manufacturing complexity, and inflation.
  • Net Price Trends: Negotiated rebates, discounts, and value-based arrangements are obscuring list prices, making net prices more relevant for analysis.

Factors Affecting Prices

  • Market Exclusivity & Patent Status: Patent expirations typically lead to significant price reductions due to generic competition.
  • Manufacturing Costs: Supply chain issues and raw material costs influence pricing.
  • Value Demonstration: Demonstrations of superior efficacy or safety can justify premium pricing.

Price Projections and Future Outlook

Short-Term (Next 1–2 Years)

  • Stability in Pricing: If patent protection or exclusivity remains, prices will likely stabilize but could experience minor adjustments due to rebate negotiations.
  • Impact of Regulatory Decisions: Any FDA approvals or label expansions can affect demand and pricing.

Medium to Long-Term (3–5 Years)

  • Patent Expiry & Biosimilar Entry: Entry of biosimilars or generics could lead to price erosion, potentially by 20-50%, depending on market penetration.
  • Market Expansion: New indications, geographic expansion, or improved formulations may sustain or elevate prices.
  • Healthcare Policy Impacts: Policies emphasizing value-based care and drug price transparency may influence net reimbursement rates and negotiated prices.

Factors Shaping Future Prices

  • Emergent Competitive Products: Development of superior therapeutic agents could diminish demand.
  • Patient Access Programs: Manufacturer initiatives like discounts or coupons can impact effective prices.
  • Cost-of-Delivery & Manufacturing: Innovations reducing costs may support price stability or reductions.

Regulatory and Economic Influences

Regulatory shifts around drug pricing transparency and health policy reforms could introduce price caps or increased scrutiny, reducing profit margins. Economic factors, including inflation and currency variations, may influence raw material costs and, consequently, drug prices.


Implications for Stakeholders

  • Manufacturers: Should monitor patent landscapes and innovative R&D to defend or extend market exclusivity.
  • Payers: Need to optimize formulary placement and negotiate rebates to manage expenditures.
  • Investors: Opportunities exist in innovation or market expansion, but risks from biosimilar competition warrant prudent analysis.

Key Takeaways

  • Market Dynamics: The demand for NDC 42291-0347 is strongly influenced by disease prevalence and treatment patterns; competitive pressures from generics or biosimilars are imminent or ongoing.
  • Price Trends: Historically stable with incremental growth; significant reductions anticipated post-patent expiry.
  • Forecast Outlook: Short-term prices are likely stable; medium-term prospects depend on patent protections, new therapeutic alternatives, and regulatory changes.
  • Strategic Considerations: Companies must innovate, expand indications, and navigate reimbursement landscapes to sustain pricing power.
  • Policy Risks: Evolving healthcare policies aiming to control drug costs can impact revenue streams and price margins.

Conclusion

The price trajectory for NDC 42291-0347 embodies a complex interplay of patent status, competitive forces, regulatory environment, and market demand. Stakeholders with nuanced, proactive strategies will be best positioned to navigate future challenges and opportunities.


FAQs

1. How does patent expiration affect the pricing of NDC 42291-0347?
Patent expiration typically exposes the product to generic or biosimilar competition, leading to substantial price reductions—often between 20-50%. The timing of this shift critically influences revenue projections and market share.

2. What factors could influence demand growth for this drug?
Demand hinges on evolving treatment guidelines, the prevalence of the target condition, FDA label expansions, and clinical adoption. Competitive advances or new indications can also increase market potential.

3. How significant are rebates and discounts in determining the net price of this drug?
Rebates and discounts negotiated with payers and pharmacy benefit managers can substantially reduce the list price, often representing 20-30% or more, thereby affecting the net price and profitability.

4. What role do regulatory policies play in the drug's market stability?
Regulatory decisions surrounding approval, labeling, safety, and pricing transparency can either bolster market exclusivity or accelerate generic entry, affecting both demand and pricing.

5. Is there potential for price increases through value-based arrangements?
Value-based contracts linking payment to treatment outcomes can enable manufacturers to justify higher prices if clinical benefits are demonstrated, but such arrangements are complex and varying across payers.


Sources
[1] U.S. Food and Drug Administration (FDA). Drug Approvals and Labeling.
[2] IQVIA. National Sales Perspective and Market Trends.
[3] Centers for Disease Control and Prevention (CDC). Disease Prevalence and Epidemiology Data.
[4] Health Policy Review Articles.
[5] Pharmaceutical Industry Reports.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.